

Connecticut Medicaid P&T Meeting Minutes

May 6th, 2021

Due to the COVID-19 outbreak, the Meeting was conducted via teleconference. The meeting was called to order at 6:01 PM.

Attendance:

P&T Members Present:

Carl Sherter

Kevin Chamberlin

Manage Nissanka

Emmett Sullivan

Vijay Chhabra

Charles Thompson

Alyssa Bennett

Sabrina Griswold

Gaye Hyre

Karina Berg

Cynthia Wilson

DSS:

Herman Kranc

Jason Gott

DXC/Magellan:

Kathy Novak

Carly Whitehouse

Joseph Morasutti

Margaret Stroczkowski

Naana Osei-Boateng

Opening Remarks & New Business:

Carl Sherter thanked the members and community for attending the P&T Teleconference and called the meeting to order at 6:01 pm. Herman Kranc, from the Department of Social Services, took a moment to announce a brief communication regarding the responsibilities of the P&T Committee. Thereafter, Carl Sherter requested the committee to vote on the 2021 Updated Bylaws. Kevin Chamberlin made a motion to approve the updated Bylaws, Gaye Hyre seconded the motion it passed unanimously by the remaining attending members of the committee. Next order of business was the nomination and reelection of P&T Chairperson and P&T Vice Chairperson. Kevin Chamberlin nominated Carl Sherter to be P&T Chairperson. The nomination was seconded by Emmett Sullivan and passed unanimously by the committee. Following the P&T Chairperson vote, Vijay Chhabra nominated Kevin Chamberlin to be the P&T Vice Chairperson. The nomination was seconded by Emmett Sullivan and passed unanimously by the committee. Lastly the Minutes from the previous meeting, held November 5th, 2020, were unanimously approved by all committee members present.

Public Presentations:

1. ANTIMIGRAINE AGENTS, OTHER

a. Nurtec ODT

Tammy Martin, APRN, Biohaven

b. Aimovig

Gene Muise, RPh, Amgen

2. HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS
 - a. Rybelsus, Ozempic David Domenichini MD, Endocrinology & Internal
 - b. Rybelsus Niki Patel, PharmD, Novo Nordisk
3. LIPOTROPICS, OTHER
 - a. Repatha Gene Muise, RPh, Amgen
4. MULTIPLE SCLEROSIS AGENTS
 - a. Kesimpta Beth D'Ambrosio, PharmD, Novartis
 - b. Zeposia John Donovan, Bristol Myers Squibb
5. OPIATE DEPENDENCE TREATMENTS
 - a. Lucemyra Bob James, US WorldMeds
 - b. Sublocade Kenny Ng, PharmD, Indivior
6. PAH AGENTS, ORAL AND INHALED
 - a. Orenitram ER Christine Hui, PharmD, United Therapeutics

The rest of the scheduled speakers waived their right to speak because either their drug was recommended to be preferred on the PDL, or they were not in attendance.

Therapeutic Class Reviews in Alphabetical Order:

ACNE AGENTS, TOPICAL

The recommendations were presented to the committee with the following changes; EPIDUO FORTE GEL W/PUMP (TOPICAL) to become Preferred and AZELEX (TOPICAL) to become Non-Preferred. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: BENZOYL PEROXIDE 10% WASH OTC (TOPICAL), BENZOYL PEROXIDE 5% WASH OTC (TOPICAL), BENZOYL PEROXIDE 6% CLEANSER OTC (TOPICAL), BENZOYL PEROXIDE GEL OTC (TOPICAL), BENZOYL PEROXIDE LOTION OTC (TOPICAL), CLINDAMYCIN / BENZOYL PEROXIDE (DUAC) (TOPICAL), CLINDAMYCIN PHOSPHATE MED. SWAB (TOPICAL), CLINDAMYCIN PHOSPHATE SOLUTION (TOPICAL), DIFFERIN CREAM (TOPICAL), DIFFERIN GEL PUMP (TOPICAL), DIFFERIN LOTION (TOPICAL), EPIDUO FORTE GEL W/PUMP (TOPICAL), ERYTHROMYCIN SOLUTION (TOPICAL), RETIN-A CREAM (TOPICAL), RETIN-A GEL (TOPICAL)

ANALGESICS, NARCOTICS SHORT

The recommendations were presented to the committee with the following changes: HYDROCODONE / IBUPROFEN (ORAL), CODEINE (ORAL), TRAMADOL 100 MG (ORAL) and OXYCODONE / APAP TABLET (PROLATE) (ORAL) to become Non-Preferred. After discussion on the recommendations, Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: APAP / CODEINE ELIXIR (ORAL), APAP / CODEINE TABLET (ORAL), HYDROCODONE / APAP SOLUTION (ORAL), HYDROCODONE / APAP TABLET (ORAL), HYDROMORPHONE TABLET (ORAL), MORPHINE CONC SOLUTION (ORAL), MORPHINE DISP SYRIN (ORAL), MORPHINE IR TABLET (ORAL), MORPHINE SOLUTION (ORAL), OXYCODONE / APAP TABLET (ORAL), OXYCODONE SOLUTION (ORAL), OXYCODONE TABLET (ORAL), TRAMADOL (ORAL), TRAMADOL / APAP (ORAL)

ANDROGENIC AGENTS

The recommendations were presented to the committee with the following changes: ANDROGEL GEL PUMP (TRANSDERM) to become Preferred and TESTOSTERONE GEL PUMP (ANDROGEL) (TRANSDERM), TESTOSTERONE GEL PACKET (AG) (VOGELXO) (TRANSDERM), TESTOSTERONE GEL PUMP (AG) (VOGELXO) (TRANSDERM), TESTOSTERONE GEL PUMP (AG) (ANDROGEL) (TRANSDERM), TESTOSTERONE GEL (AG) (VOGELXO) (TRANSDERM) and TESTOSTERONE GEL (VOGELXO) (TRANSDERM). Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: ANDROGEL GEL PUMP (TRANSDERM)

ANGIOTENSIN MODULATOR COMBINATIONS

The recommendations were presented to the committee with the following change; AMLODIPINE / VALSARTAN / HCTZ (ORAL) to become Non-Preferred. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Manage Nissanka then passed unanimously by the Committee.

ON PDL: AMLODIPINE / BENAZEPRIL (ORAL), AMLODIPINE / OLMESARTAN (AG) (ORAL), AMLODIPINE / OLMESARTAN (ORAL), AMLODIPINE / VALSARTAN (AG) (ORAL), AMLODIPINE / VALSARTAN (ORAL)

ANGIOTENSIN MODULATORS

The recommendations were presented to the committee with the following changes; BENAZEPRIL (ORAL), OLMESARTAN HCTZ (ORAL), OLMESARTAN HCTZ (AG) (ORAL), OLMESARTAN (AG) (ORAL) and OLMESARTAN (ORAL) to become Preferred. The scheduled speaker waved their right to speak. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Alyssa Bennett then passed unanimously by the Committee.

ON PDL: BENAZEPRIL (ORAL), DIOVAN (ORAL), ENALAPRIL (ORAL), ENALAPRIL HCTZ (ORAL), ENTRESTO (ORAL), IRBESARTAN (ORAL), IRBESARTAN HCTZ (ORAL), LISINAPRIL (ORAL), LISINAPRIL HCTZ (ORAL), LOSARTAN (ORAL), LOSARTAN HCTZ (ORAL), OLMESARTAN (AG) (ORAL), OLMESARTAN (ORAL), OLMESARTAN HCTZ (AG) (ORAL), OLMESARTAN HCTZ (ORAL), QUINAPRIL (ORAL), QUINAPRIL HCTZ (ORAL), RAMIPRIL (ORAL), VALSARTAN HCTZ (ORAL)

ANTIBIOTICS, GI

The recommendations were presented to the committee with the following changes: TINIDAZOLE (ORAL), VANCOMYCIN CAPSULE (AG) (ORAL) and VANCOMYCIN CAPSULE (ORAL) to become Preferred. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: FIRVANQ (ORAL), METRONIDAZOLE TABLET (ORAL), TINIDAZOLE (ORAL), VANCOMYCIN CAPSULE (AG) (ORAL), VANCOMYCIN CAPSULE (ORAL)

ANTIBIOTICS, INHALED

The recommendations were presented and there were no changes from the previous year. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: BETHKIS (INHALATION), KITABIS PAK (INHALATION), TOBI PODHALER (INHALATION)

ANTIBIOTICS, TOPICAL

The recommendations were presented and there were no changes from the previous year. Vijay Chhabra motioned to accept the recommendations as presented, the motion was seconded by Kevin Chamberlin then passed unanimously by the Committee.

ON PDL: GENTAMICIN CREAM (TOPICAL), GENTAMICIN OINTMENT (TOPICAL), MUPIROCIN OINTMENT (TOPICAL)
ANTIBIOTICS, VAGINAL

The recommendations were presented to the committee with the following change: VANDAZOLE (VAGINAL) to become Non-Preferred. After review and discussion, Alyssa Bennett made a motion to accept the recommendations with the addition of METRONIDAZOLE (VAGINAL), the motion was seconded by Kevin Chamberlin then passed unanimously by the Committee.

ON PDL: CLEOCIN OVULES (VAGINAL), CLINDESSE (VAGINAL), METRONIDAZOLE (VAGINAL), NUVESSA (VAGINAL)
ANTICOAGULANTS

The recommendations were presented and there were no changes from the previous year. The scheduled speaker waived their right to speak. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: ELIQUIS (ORAL), ELIQUIS DOSE PACK (ORAL), ENOXAPARIN SODIUM VIAL (AG) (SUBCUTANEOUS), ENOXAPARIN SODIUM VIAL (SUBCUTANEOUS), ENOXAPARIN SYRINGE (AG) (SUBCUTANE.), ENOXAPARIN SYRINGE (SUBCUTANE.), PRADAXA (ORAL), WARFARIN (ORAL), XARELTO (ORAL), XARELTO DOSE PACK (ORAL)

ANTIEMETIC/ANTIVERTIGO AGENTS

The recommendations were presented to the committee with the following change: EMEND CAPSULE (ORAL) to become Preferred. Vijay Chhabra motioned to accept the recommendations as presented, the motion was seconded by Kevin Chamberlin then passed unanimously by the Committee.

ON PDL: DICLEGIS (ORAL), DRONABINOL (ORAL), EMEND CAPSULE (ORAL), ONDANSETRON ODT (ORAL), ONDANSETRON SOLUTION (ORAL), ONDANSETRON TABLETS (ORAL)

ANTIFUNGALS, ORAL

The recommendations were presented to the committee with the following change: NOXAFIL TABLET (ORAL) to become Preferred. Vijay Chhabra motioned to accept the recommendations as presented, the motion was seconded by Kevin Chamberlin then passed unanimously by the Committee.

ON PDL: CLOTRIMAZOLE (MUCOUS MEM), FLUCONAZOLE SUSPENSION (ORAL), FLUCONAZOLE TABLET (ORAL), GRISEOFULVIN SUSPENSION (ORAL), NOXAFIL TABLET (ORAL), NYSTATIN SUSPENSION (ORAL), TERBINAFINE (ORAL)

ANTIFUNGALS, TOPICAL

The recommendations were presented to the committee with the following changes: NYSTATIN-TRIAMCINOLONE OINT (TOPICAL) and NYSTATIN-TRIAMCINOLONE CREAM (TOPICAL) to become Preferred. Kevin Chamberlin made a motion to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: CLOTRIMAZOLE CREAM OTC (TOPICAL), CLOTRIMAZOLE CREAM RX (TOPICAL), CLOTRIMAZOLE SOLUTION RX (TOPICAL), CLOTRIMAZOLE-BETAMETHASONE CREAM (TOPICAL), KETOCONAZOLE CREAM (TOPICAL),

KETOCONAZOLE SHAMPOO (TOPICAL), MICONAZOLE CREAM OTC (TOPICAL), MICONAZOLE POWDER OTC (TOPICAL), NYSTATIN CREAM (TOPICAL), NYSTATIN OINT (TOPICAL), NYSTATIN POWDER (TOPICAL), NYSTATIN-TRIAMCINOLONE CREAM (TOPICAL), NYSTATIN-TRIAMCINOLONE OINT (TOPICAL)

ANTIMIGRAINE AGENTS, OTHER

The recommendations were presented to the committee with the following changes: UBRELVY (ORAL) to become Preferred and NURTEC ODT (ORAL) and DIHYDROERGOTAMINE MESYLATE (NASAL) to become Non-Preferred. Gene Muise from Amgen provided testimony in favor of adding Aimovig to the PDL. Tammy Martin from Biohaven provided testimony in favor of leaving Nurtec ODT as preferred on the PDL. The other scheduled speakers waved their right to speak. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: AJOVY (SUBCUTANEOUS), AJOVY AUTOINJECTOR (SUBCUTANEOUS), AJOVY AUTOINJECTOR 3-PK (SUBCUTANEOUS), EMGALITY PEN (SUBCUTANEOUS), EMGALITY SYRINGE 120 MG (SUBCUTANEOUS), UBRELVY (ORAL)

ANTIMIGRAINE AGENTS, TRIPTANS

The recommendations were presented to the committee with the following changes: IMITREX (NASAL) to become Preferred and SUMATRIPTAN (AG) (NASAL) and SUMATRIPTAN (NASAL) to become Non-Preferred. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: ELETRIPTAN (AG) (ORAL), ELETRIPTAN (ORAL), IMITREX (NASAL), RIZATRIPTAN ODT (ORAL), RIZATRIPTAN TABLET (ORAL), SUMATRIPTAN (ORAL), SUMATRIPTAN DISP SYRIN (SUBCUTANE.), SUMATRIPTAN VIAL (SUBCUTANE.)

ANTIPARASITICS, TOPICAL

The recommendations were presented and there were no changes from the previous year. Kevin Chamberlin made a motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: NATROBA (TOPICAL), PERMETHRIN CREAM (TOPICAL), PERMETHRIN OTC (TOPICAL), PIPERONYL BUTOXIDE/PYRETHRINS SHAMPOO OTC (TOPICAL)

ANTIVIRALS, ORAL

The recommendations were presented and there were no changes from the previous year. Vijay Chhabra made a motioned to accept the recommendations as presented, the motion was seconded by Kevin Chamberlin then passed unanimously by the Committee.

ON PDL: ACYCLOVIR CAPSULE (ORAL), ACYCLOVIR SUSPENSION (ORAL), ACYCLOVIR TABLET (ORAL), FAMCICLOVIR (ORAL), OSELTAMIVIR CAPSULE (ORAL), OSELTAMIVIR SUSPENSION (ORAL), VALACYCLOVIR (ORAL)

ANTIVIRALS, TOPICAL

The recommendations were presented and there were no changes from the previous year. Vijay Chhabra made a motioned to accept the recommendations as presented, the motion was seconded by Kevin Chamberlin then passed unanimously by the Committee.

ON PDL: ZOVIRAX CREAM (TOPICAL), ZOVIRAX OINTMENT (TOPICAL)

BETA-BLOCKERS

The recommendations were presented and there were no changes from the previous year. Vijay Chhabra made a motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: ATENOLOL (ORAL), ATENOLOL / CHLORTHALIDONE (ORAL), BISOPROLOL (ORAL), CARVEDILOL (ORAL), LABETALOL (ORAL), METOPROLOL (ORAL), METOPROLOL XL (AG) (ORAL), METOPROLOL XL (ORAL), PROPRANOLOL ER (AG) (ORAL), ROPRANOLOL ER (ORAL), PROPRANOLOL SOLUTION (ORAL), PROPRANOLOL TABLET (ORAL), SOTALOL (ORAL)

BLADDER RELAXANT PREPARATIONS

The recommendations were presented and there were no changes from the previous year. Vijay Chhabra made a motioned to accept the recommendations as presented, the motion was seconded by Kevin Chamberlin then passed unanimously by the Committee.

ON PDL: OXYBUTYNIN ER (ORAL), OXYBUTYNIN SYRUP (ORAL), OXYBUTYNIN TABLET (ORAL), SOLIFENACIN (ORAL), TOVIAZ (ORAL)

BONE RESORPTION SUPPRESSION AND RELATED AGENTS

The recommendations were presented to the committee with the following changes: TERIPARATIDE (BRAND) (SUBCUTANEOUS) to become Preferred and FORTEO (SUBCUTANE.) to become Non-Preferred. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Manage Nissanka then passed unanimously by the Committee.

ON PDL: ALENDRONATE TABLETS (ORAL), CALCITONIN SALMON (NASAL), IBANDRONATE TABLETS (ORAL), TERIPARATIDE (BRAND) (SUBCUTANEOUS)

BPH TREATMENTS

The recommendations were presented and there were no changes from the previous year. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: ALFUZOSIN (ORAL), DOXAZOSIN (ORAL), DUTASTERIDE (ORAL), FINASTERIDE (ORAL), TAMSULOSIN (ORAL), TERAZOSIN (ORAL)

CALCIUM CHANNEL BLOCKERS

The recommendations were presented and there were no changes from the previous year. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: AMLODIPINE (ORAL), DILTIAZEM CAPSULE ER (ORAL), DILTIAZEM TABLET (ORAL), FELODIPINE ER (ORAL), NIFEDIPINE ER (ORAL), VERAPAMIL TABLET (ORAL), VERAPAMIL TABLET ER (ORAL)

CEPHALOSPORINS AND RELATED ANTIBIOTICS

The recommendations were presented to the committee with the following change: AMOXICILLIN/CLAV SUSPENSION (AG) (ORAL) to become Preferred. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Emmett Sullivan then passed unanimously by the Committee.

ON PDL: AMOXICILLIN/CLAV SUSPENSION (AG) (ORAL), AMOXICILLIN/CLAV SUSPENSION (ORAL), AMOXICILLIN/CLAV TABLET (AG) (ORAL), AMOXICILLIN/CLAV TABLET (ORAL), CEFACLOR CAPSULE (ORAL), CEFADROXIL CAPSULE (ORAL), CEFADROXIL SUSPENSION (ORAL), CEFDINIR CAPSULE (ORAL), CEFDINIR SUSPENSION (ORAL), CEFPROZIL SUSPENSION (ORAL), CEFPROZIL TABLET (ORAL), CEFUROXIME TABLET (ORAL), CEPHALEXIN CAPSULE (ORAL), CEPHALEXIN SUSPENSION (ORAL)

CONTRACEPTIVES, ORAL

The recommendations were presented to the committee with the following changes: MELODETTA 24 FE (ORAL) and CHARLOTTE 24 FE (ORAL) to become Preferred and MINASTRIN 24 FE (ORAL), OPTION 2 OTC (ORAL), MY CHOICE OTC (ORAL) and LEVONORGESTREL OTC (ORAL) to become Non-Preferred. Alyssa Bennett made a motion to accept the recommendations as presented, the motion was seconded by Gaye Hyre then passed unanimously by the Committee.

ON PDL: AFTERA OTC (ORAL), ALTAVERA (ORAL), ALYACEN MONOPHASIC (ORAL), AMETHIA (ORAL), APRI (ORAL), AUBRA (ORAL), AUROVELA (ORAL), AUROVELA FE (ORAL), AVIANE (ORAL), BLISOVI FE (ORAL), CAMILA (ORAL), CHARLOTTE 24 FE (ORAL), CHATEAL (ORAL), CYCLAFEM MONOPHASIC (ORAL), CYCLAFEM TRIPHASIC (ORAL), DASETTA MONOPHASIC (ORAL), DEBLITANE (ORAL), DESOGESTREL/ETHINYL ESTRADIOL (ORAL), ELINEST (ORAL), ELLA (ORAL), EMOQUETTE (ORAL), ENSKYCE (ORAL), ERRIN (ORAL), ESTARYLLA (ORAL), ETHINYL ESTRADIOL/DROSPIRENONE (ORAL), ETHINYL ESTRADIOL/DROSPIRENONE MONOPHASIC (ORAL), ETHYNODIOL/ETHINYL ESTRADIOL (ORAL), FALMINA (ORAL), GIANVI (ORAL), HEATHER (ORAL), ISIBLOOM (ORAL), JENCYCLA (ORAL), JULEBER (ORAL), JUNEL (ORAL), JUNEL FE (ORAL), KURVELO (ORAL), LARIN FE (ORAL), LARISSIA (ORAL), LESSINA (ORAL), LEVONORGESTREL/ETHINYL ESTRADIOL MONOPHASIC (LUPIN) (ORAL), LEVONORGESTREL/ETHINYL ESTRADIOL MONOPHASIC (MYLAN) (ORAL), LEVORA (ORAL), LILLOW (ORAL), LOESTRIN (ORAL), LOESTRIN FE (ORAL), LORYNA (ORAL), LOSEASONIQUE (ORAL), LOW-OGESTREL (ORAL), LO-ZUMANDIMINE (ORAL), MARLISSA (ORAL), MELODETTA 24 FE (ORAL), MICROGESTIN FE (ORAL), MILI (ORAL), MIRCETTE (ORAL), MONO-LINYAH (ORAL), NATAZIA (ORAL), NIKKI (ORAL), NORETHINDRONE (ORAL), ORETHINDRONE/ETHINYL ESTRADIOL (ORAL), NORGESTIMATE/ETHINYL ESTRADIOL MONOPHASIC (ORAL), NORGESTIMATE/ETHINYL ESTRADIOL TRIPHASIC (ORAL), NORLYDA (ORAL), PHILITH (ORAL), PIMTREA (ORAL), PIRMELLA (ORAL), PLAN B ONE-STEP OTC (ORAL), PORTIA (ORAL), PREVIFEM (ORAL), RECLIPSEN (ORAL), SEASONIQUE (ORAL), SHAROBEL (ORAL), SPRINTEC (ORAL), SRONYX (ORAL), SYEDA (ORAL), TAKE ACTION OTC (ORAL), TRI FEMYNOR (ORAL), TRI-LINYAH (ORAL), TRI-LO-ESTARYLLA (ORAL), TRI-LO-MARZIA (ORAL), TRI-LO-MILI (ORAL), TRI-LO-SPRINTEC (ORAL), TRINESSA (ORAL), TRI-PREVIFEM (ORAL), TRI-SPRINTEC (ORAL), TRIVORA (ORAL), VIENVA (ORAL), WERA (ORAL)

FLUOROQUINOLONES, ORAL

The recommendations were presented and there were no changes from the previous year. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: CIPRO SUSPENSION (ORAL), CIPROFLOXACIN TABLET (ORAL), LEVOFLOXACIN TABLET (ORAL)

GI MOTILITY, CHRONIC

The recommendations were presented and there were no changes from the previous year. Vijay Chhabra motioned to accept the recommendations as presented, the motion was seconded by Kevin Chamberlin then passed unanimously by the Committee.

ON PDL: AMITIZA (ORAL), LINZESS (ORAL), MOVANTIK (ORAL)

GLUCAGON AGENTS

The recommendations were presented and there were no changes from the previous year. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Manage Nissanka then passed unanimously by the Committee.

ON PDL: BAQSIMI (NASAL), GLUCAGON (INJECTION), GLUCAGON EMERGENCY KIT (LILLY) (INJECTION), PROGLYCEM SUSPENSION (ORAL)

GROWTH FACTORS

The recommendations were presented to the committee with the following change: EGRIFTA (SUB-Q) to become Non-Preferred. Vijay Chhabra motioned to accept the recommendations as presented, the motion was seconded by Kevin Chamberlin then passed unanimously by the Committee.

ON PDL: INCRELEX (SUB-Q)

GROWTH HORMONE

The recommendations were presented to the committee with the following changes: GENOTROPIN DISP SYRIN (INJECTION) and GENOTROPIN CARTRIDGE (INJECTION) to become Preferred and NUTROPIN AQ PEN (INJECTION) to become Non-Preferred. Emmett Sullivan motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: GENOTROPIN CARTRIDGE (INJECTION), GENOTROPIN DISP SYRIN (INJECTION), NORDITROPIN PEN (INJECTION)

H. PYLORI TREATMENT

The recommendations were presented to the committee with the following change: HELIDAC (ORAL) to become Non-Preferred. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: PYLERA (ORAL)

HEPATITIS C AGENTS

The recommendations were presented to the committee with the following change: SOFOSBUVIR/VELPATASVIR (AG) (ORAL) to become Preferred and EPCLUSA (ORAL) to become Non-Preferred. The scheduled speakers waived their right to speak. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: PEGASYS SYRINGE (SUB-Q), PEGASYS VIAL (SUBCUTANE.), PEG-INTRON (SUBCUTANE.), RIBAVIRIN TABLET (ORAL), MAVYRET (ORAL) (8 WEEKS), SOFOSBUVIR/VELPATASVIR (AG) (ORAL), VOSEVI (ORAL) (12 WEEKS)

HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS

The recommendations were presented and there were no changes from the previous year. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: ACARBOSE (ORAL), GLYSET (ORAL)

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS

The recommendations were presented to the committee with the following change: OZEMPIC (SUBCUTANE.) to become Non-Preferred. David Domenichini from Endocrinology and Internal Medicine provided testimony in favor of adding Rybelsus and leaving Ozempic as a preferred agent on the PDL. Niki Patel from Novo Nordisk provided testimony in favor of adding Rybelsus as a preferred agent to the PDL. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: BYDUREON PENS (SUBCUTANE.), BYETTA PENS (SUBCUTANE.), GLYXAMBI (ORAL), JANUMET (ORAL), JANUMET XR (ORAL), JANUVIA (ORAL), JENTADUETO (ORAL), ONGLYZA (ORAL), TRADJENTA (ORAL), TRULICITY (SUBCUTANE.), VICTOZA (SUBCUTANE.)

HYPOGLYCEMICS, INSULIN AND RELATED AGENTS

The recommendations were presented to the committee with the following changes: INSULIN ASPART/INSULIN ASPART PROTAMINE VIAL (AG) (SUBCUTANEOUS), INSULIN LISPRO PROTAMINE MIX KWIKPEN (AG) (SUBCUTANEOUS), INSULIN ASPART/INSULIN ASPART PROTAMINE INSULIN PEN (AG) (SUBCUTANEOUS), INSULIN ASPART VIAL (AG) (SUBCUTANEOUS), INSULIN ASPART CARTRIDGE (AG) (SUBCUTANEOUS), INSULIN LISPRO VIAL (AG) (SUBCUTANEOUS), INSULIN ASPART PEN (AG) (SUBCUTANEOUS), INSULIN LISPRO PEN (AG) (SUBCUTANEOUS) and INSULIN LISPRO JUNIOR KWIKPEN (AG) (SUBCUTANEOUS) to Preferred. HUMULIN PEN OTC (SUBCUTANE.), TRESIBA FLEXTOUCH 100 U/ML PEN (SUBCUTANEOUS) and TRESIBA FLEXTOUCH 200 U/ML PEN (SUBCUTANEOUS) to Non-preferred. After committee discussion, Alyssa Bennett made a motion to accept the recommendations as presented with the addition of TRESIBA FLEXTOUCH 100 U/ML PEN (SUBCUTANEOUS) and TRESIBA FLEXTOUCH 200 U/ML PEN (SUBCUTANEOUS) to the PDL. Emmett Sullivan seconded the motion and it was passed unanimously by the remaining committee members.

ON PDL: HUMALOG CARTRIDGE (SUBCUTANE.), HUMALOG JUNIOR KWIKPEN (SUBCUTANE.), HUMALOG MIX PEN (SUBCUTANE.), HUMALOG MIX VIAL (SUBCUTANE.), HUMALOG PEN (SUBCUTANE.), HUMALOG VIAL (SUBCUTANE.), HUMULIN 500 U/M PEN (SUBCUTANE.), HUMULIN 500 U/M VIAL (SUBCUTANE.), HUMULIN 70/30 PEN OTC (SUBCUTANE.), HUMULIN 70/30 VIAL OTC (SUBCUTANE.), HUMULIN VIAL OTC (SUBCUTANE.), INSULIN ASPART CARTRIDGE (AG) (SUBCUTANEOUS), INSULIN ASPART PEN (AG) (SUBCUTANEOUS), INSULIN ASPART VIAL (AG) (SUBCUTANEOUS), INSULIN ASPART/INSULIN ASPART PROTAMINE INSULIN PEN (AG) (SUBCUTANEOUS), INSULIN ASPART/INSULIN ASPART PROTAMINE VIAL (AG) (SUBCUTANEOUS), INSULIN LISPRO JUNIOR KWIKPEN (AG) (SUBCUTANEOUS), INSULIN LISPRO PEN (AG) (SUBCUTANEOUS), INSULIN LISPRO PROTAMINE MIX KWIKPEN (AG) (SUBCUTANEOUS), INSULIN LISPRO VIAL (AG) (SUBCUTANEOUS), LANTUS SOLOSTAR PEN (SUBCUTANE.), LANTUS VIAL (SUBCUTANE.), LEVEMIR PENS (SUBCUTANE.), LEVEMIR VIAL (SUBCUTANE.), NOVOLOG CARTRIDGE (SUBCUTANE.), NOVOLOG MIX PEN (SUBCUTANE.), NOVOLOG MIX VIAL (SUBCUTANE.), NOVOLOG PEN (SUBCUTANE.), NOVOLOG VIAL (SUBCUTANE.), TRESIBA FLEXTOUCH 100 U/ML PEN (SUBCUTANEOUS), TRESIBA FLEXTOUCH 200 U/ML PEN (SUBCUTANEOUS)

HYPOGLYCEMICS, MEGLITINIDES

The recommendations were presented and there were no changes from the previous year. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Emmett Sullivan then passed unanimously by the Committee.

ON PDL: NATEGLINIDE (ORAL), REPAGLINIDE (ORAL)

HYPOGLYCEMICS, METFORMINS

The recommendations were presented and there were no changes from the previous year. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: GLIPIZIDE-METFORMIN (ORAL), GLYBURIDE-METFORMIN (ORAL), METFORMIN (ORAL), METFORMIN ER (GLUCOPHAGE XR) (ORAL)

HYPOGLYCEMICS, SGLT2

The recommendations were presented and there were no changes from the previous year. Vijay Chhabra motioned to accept the recommendations as presented, the motion was seconded by Kevin Chamberlin then passed unanimously by the Committee.

ON PDL: FARXIGA (ORAL), INVOKAMET (ORAL), INVOKANA (ORAL), JARDIANCE (ORAL), SYNJARDY (ORAL), XIGDUO XR (ORAL)

HYPOGLYCEMICS, TZD

The recommendations were presented and there were no changes from the previous year. Vijay Chhabra motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: PIOGLITAZONE (ORAL)

IMMUNOSUPPRESSIVES, ORAL

The recommendations were presented to the committee with the following changes: EVEROLIMUS TABLET (ZORTRESS) (ORAL) to become Preferred. Vijay Chhabra motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: AZATHIOPRINE (ORAL), CYCLOSPORINE, MODIFIED CAPSULE (ORAL), CYCLOSPORINE, MODIFIED SOLUTION (ORAL), EVEROLIMUS TABLET (ZORTRESS) (ORAL), MYCOPHENOLATE MOFETIL CAPSULE (ORAL), MYCOPHENOLATE MOFETIL TABLET (ORAL), RAPAMUNE SOLUTION (ORAL), TACROLIMUS (ORAL)

LIPOTROPICS, OTHER

The recommendations were presented to the committee with the following changes: GEMFIBROZIL (AG) (ORAL), FENOFIBRATE CAPSULE (LOFIBRA) (ORAL) and FENOFIBRATE TABLET (LOFIBRA) (ORAL) to become Preferred and EVKEEZA (INTRAVEN) to become Non-Preferred. Gene Muise from Amgen provided testimony in favor of adding Repatha to the PDL. Emmett Sullivan motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: CHOLESTYRAMINE/SUCROSE (ORAL), COLESTIPOL TABLET (ORAL), EZETIMIBE (ORAL), FENOFIBRATE CAPSULE (LOFIBRA) (ORAL), FENOFIBRATE TABLET (AG) (TRICOR) (ORAL), FENOFIBRATE TABLET (LOFIBRA) (ORAL),

FENOFIBRATE TABLET (TRICOR) (ORAL), GEMFIBROZIL (AG) (ORAL), GEMFIBROZIL (ORAL), NIACIN CAPSULE ER OTC (ORAL), NIACIN ER (ORAL), NIACIN TABLET ER OTC (ORAL), NIACIN TABLET OTC (ORAL), OMEGA-3 ACID ETHYL ESTERS (ORAL), OMEGA-3 OTC (ORAL)

LIPOTROPICS, STATINS

The recommendations were presented and there were no changes from the previous year. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: ATORVASTATIN (ORAL), LOVASTATIN (ORAL), PRAVASTATIN (ORAL), ROSUVASTATIN (ORAL), SIMVASTATIN TABLET (ORAL)

MACROLIDES/KETOLIDES

The recommendations were presented and there were no changes from the previous year. Vijay Chhabra motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: AZITHROMYCIN PACKET (AG) (ORAL), AZITHROMYCIN SUSPENSION (ORAL), AZITHROMYCIN TABLET (ORAL), CLARITHROMYCIN TABLET (ORAL), E.E.S. 200 SUSPENSION (ORAL), ERY-TAB (ORAL), ERYTHROMYCIN BASE CAPSULE DR (ORAL)

MULTIPLE SCLEROSIS AGENTS

The recommendations were presented to the committee with the following changes: AUBAGIO (ORAL) and GILENYA (ORAL) to become Non-Preferred. Beth D'Ambrosio from Novartis provided testimony in favor of adding Kesimpta to the PDL. John Donovan from Bristol Meyers Squibb provided testimony in favor of adding Zeposia to the PDL. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: AVONEX (INTRAMUSC.), AVONEX PEN (INTRAMUSC.), BETASERON KIT (SUBCUTANE.), COPAXONE 20 MG/ML (SUBCUTANE.), TECFIDERA (ORAL), TECFIDERA STARTER PACK (ORAL)

OPIATE DEPENDENCE TREATMENTS

The recommendations were presented to the committee with the following changes: BUPRENORPHINE/NALOXONE TAB (SUBLINGUAL) to become Preferred. Bob James from US WorldMeds provided testimony in favor of adding Lucemyra to the PDL and Kenny Ng from Indivior provided testimony in favor of adding Sublocade to the PDL. The other scheduled speakers waved their right or were unable to speak. After initial discussion, Manage Nissanka made a motion to accept the recommendations with the addition of Sublocade. After further discussion. Emmett Sullivan motioned to accept the recommendations as originally presented, the motion was seconded by Kevin Chamberlin then passed unanimously by the Committee.

ON PDL: BUPRENORPHINE HCL (SUBLINGUAL), BUPRENORPHINE/NALOXONE TAB (SUBLINGUAL), NALOXONE SYRINGE (INJECTION), NALOXONE VIAL (INJECTION), NALTREXONE (ORAL), NARCAN SPRAY (NASAL), SUBOXONE FILM (SUBLINGUAL), VIVITROL (INTRAMUSC)

PAH AGENTS, ORAL AND INHALED

The recommendations were presented to the committee with the following changes: LETAIRIS (ORAL) to become Preferred and AMBRISANTAN (ORAL) and REVATIO SUSPENSION (ORAL) to become Non-Preferred. Christine Hui

from United Therapeutics provided testimony in favor of adding Orenitram ER to the PDL. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: LETAIRIS (ORAL), SILDENAFIL TABLET (ORAL), TADALAFIL (ADCIRCA) (ORAL), TRACLEER TABLET (ORAL), VENTAVIS (INHALATION)

PANCREATIC ENZYMES

The recommendations were presented and there were no changes from the previous year. The scheduled speaker waived their right to speak. Vijay Chhabra motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: CREON (ORAL), ZENPEP (ORAL)

PHOSPHATE BINDERS

The recommendations were presented to the committee with the following changes: RENVELA TABLET (ORAL) to become Preferred and SEVELAMER CARBONATE TABLET (AG) (ORAL) and SEVELAMER CARBONATE TABLET (ORAL) to become Non-Preferred. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: CALCIUM ACETATE CAPSULE (ORAL), CALCIUM ACETATE TABLET (ORAL), RENVELA TABLET (ORAL)

PITUITARY SUPPRESSIVE AGENTS, LHRH

The recommendations were presented to the committee with the following change: FENSOLVI (SUBCUTANEOUS) to become Preferred. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: ELIGARD (SUB-Q), FENSOLVI (SUBCUTANEOUS), LEUPROLIDE ACETATE (SUB-Q), LUPANETA PACK (INJECTION/ORAL), LUPRON DEPOT (INTRAMUSC), LUPRON DEPOT KIT (INJECTION), LUPRONJ DEPOT-PED (INJECTION), LUPRONJ DEPOT-PED KIT (INJECTION), SYNAREL (NASAL), ZOLADEX (SUB-Q)

PLATELET AGGREGATION INHIBITORS

The recommendations were presented to the committee with the following changes: ASPIRIN/DIPYRIDAMOLE (AG) (ORAL) to become Preferred. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: ASPIRIN/DIPYRIDAMOLE (AG) (ORAL), BRILINTA (ORAL), CLOPIDOGREL (ORAL), DIPYRIDAMOLE (ORAL), PRASUGREL (ORAL)

POTASSIUM BINDERS

The recommendations were presented and there were no changes from the previous year. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: LOKELMA (ORAL), SODIUM POLYSTYRENE SULFONATE (ORAL)

PRENATAL VITAMINS

The recommendations were presented to the committee with the following changes: PNV COMBO#47/IRON/FA #1/DHA (ORAL) and PRENATAL VIT/FE FUMARATE/FA OTC (ORAL) to become Preferred and PNV 11-IRON FUM-FOLIC ACID-OM3 (ORAL), PNV#16/IRON FUM & PS/FA/OM-3 (ORAL), PNV53/IRON B-G HCL-P/FA/OMEGA3 (ORAL) and VITAFOL FE+ (ORAL) to become Non-Preferred. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: CITRANATAL B-CALM (ORAL), COMPLETENATE CHEW TABLET (ORAL), PNV COMBO#47/IRON/FA #1/DHA (ORAL), PNV NO.15/IRON FUM & PS CMP/FA (ORAL), PNV WITH CA,NO.72/IRON/FA (ORAL), PNV WITH CA,NO.74/IRON/FA OTC (ORAL), PNV119/IRON FUMARATE/FA/DSS TABLET (ORAL), PNV2/IRON B-G SUC-P/FA/OMEGA-3 (ORAL), PRENATAL VIT #76/IRON,CARB/FA (ORAL), PRENATAL VIT NO.78/IRON/FA (ORAL), PRENATAL VIT/FE FUMARATE/FA OTC (ORAL), SELECT-OB + DHA (ORAL), TRICARE (ORAL), TRINATAL RX 1 (ORAL), VITAFOL NANO (ORAL), VITAFOL TAB CHEW (ORAL), VITAFOL ULTRA (ORAL), VITAFOL-OB (ORAL), VITAFOL-OB+DHA (ORAL), VITAFOL-ONE (ORAL), VOL-PLUS (ORAL)

PROTON PUMP INHIBITORS

The recommendations were presented to the committee with the following change: ESOMEPRAZOLE CAPSULES OTC (ORAL) to Preferred. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: ESOMEPRAZOLE CAPSULES (AG) (ORAL), ESOMEPRAZOLE CAPSULES (ORAL), ESOMEPRAZOLE CAPSULES OTC (ORAL), NEXIUM SUSPENSION (ORAL), OMEPRAZOLE (ORAL), PANTOPRAZOLE (ORAL), PROTONIX SUSPENSION (ORAL)

SKELETAL MUSCLE RELAXANTS

The recommendations were presented to the committee with the following change: CHLORZOXAZONE (ORAL) to Non-Preferred. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: BACLOFEN (ORAL), CYCLOBENZAPRINE (ORAL), METHOCARBAMOL (ORAL), TIZANIDINE TABLETS (ORAL)

TETRACYCLINES

The recommendations were presented and there were no changes from the previous year. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: DOXYCYCLINE HYCLATE CAPSULE (AG) (ORAL), DOXYCYCLINE HYCLATE CAPSULE (ORAL), DOXYCYCLINE HYCLATE TABLET (ORAL), DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE (ORAL), DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE (ORAL), DOXYCYCLINE MONOHYDRATE TABLET (ORAL), MINOCYCLINE CAPSULES (ORAL)

ULCERATIVE COLITIS AGENTS

The recommendations were presented and there were no changes from the previous year. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: APRISO (ORAL), CANASA (RECTAL), LIALDA (ORAL), PENTASA (ORAL), SULFASALAZINE (AG) (ORAL), SULFASALAZINE (ORAL), SULFASALAZINE DR (AG) (ORAL)

UTERINE DISORDER TREATMENTS

The recommendations were presented to the committee with the following change: ORIAHNN (ORAL) to Preferred. The scheduled speaker waved their right to speak. Kevin Chamberlin motioned to accept the recommendations as presented, the motion was seconded by Vijay Chhabra then passed unanimously by the Committee.

ON PDL: ORIAHNN (ORAL), ORLISSA (ORAL)

VASODILATORS, CORONARY

The recommendations were presented to the committee with the following change: ISOSORBIDE DINITRATE (AG) (ORAL) to Non-Preferred. Emmett Sullivan motioned to accept the recommendations as presented, the motion was seconded by Sabrina Griswold then passed unanimously by the Committee.

ON PDL: ISOSORBIDE DINITRATE (ORAL), ISOSORBIDE MONONITRATE (ORAL), ISOSORBIDE MONONITRATE SR (ORAL), NITRO-BID OINT. (TRANSDERM), NITROGLYCERIN (AG) (SUBLINGUAL), NITROGLYCERIN (AG) (TRANSDERM), NITROGLYCERIN (SUBLINGUAL), NITROGLYCERIN (TRANSDERM)

Recommendations for Next Class Reviews

The following classes were recommended to be reviewed at the next P&T Meeting:

1. ALZHEIMER'S AGENTS
2. ANTHELMINTICS
3. ANTI-ALLERGENS, ORAL
4. ANTICONVULSANTS
5. ANTIDEPRESSANTS, OTHER
6. ANTIDEPRESSANTS, SSRIs
7. ANTIHISTAMINES, MINIMALLY SEDATING
8. ANTIHYPERTENSIVES, SYMPATHOLYTIC
9. ANTIHYPERURICEMICS, ORAL
10. ANTIPARKINSON'S AGENTS
11. ANTIPSORIATICS, ORAL
12. ANTIPSORIATICS, TOPICAL
13. ANTIPSYCHOTICS
14. ANXIOLYTICS
15. BILE SALTS
16. BOTULINUM TOXINS
17. BRONCHODILATORS, BETA AGONIST
18. COLONY STIMULATING FACTORS
19. COPD AGENTS
20. CYTOKINE AND CAM ANTAGONISTS
21. EMOLLIENTS
22. EPINEPHRINE, SELF-INJECTED
23. ERYTHROPOIESIS STIMULATING PROTEINS
24. GLUCOCORTICOIDS, INHALED
25. GLUCOCORTICOIDS, ORAL
26. HEMOPHILIA TREATMENT
27. HISTAMINE II RECEPTOR BLOCKERS
28. IMMUNOMODULATORS, ASTHMA

29. IMMUNOMODULATORS, ATOPIC DERMATITIS
30. IMMUNOMODULATORS, TOPICAL
31. INTRANASAL RHINITIS AGENTS
32. IRON, ORAL
33. LEUKOTRIENE MODIFIERS
34. METHOTREXATE
35. MOVEMENT DISORDERS
36. NEUROPATHIC PAIN
37. NSAIDS
38. ONCOLOGY AGENTS, BREAST CANCER
39. ONCOLOGY AGENTS, HEMATOLOGIC
40. ONCOLOGY AGENTS, LUNG
41. ONCOLOGY AGENTS, OTHER
42. ONCOLOGY AGENTS, PROSTATE
43. ONCOLOGY AGENTS, RENAL CELL
44. ONCOLOGY AGENTS, SKIN
45. OPHTHALMIC ANTIBIOTICS
46. OPHTHALMIC ANTIBIOTIC-STEROID COMBINATIONS
47. OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
48. OPHTHALMIC ANTI-INFLAMMATORIES
49. OPHTHALMICS, GLAUCOMA AGENTS
50. OTIC ANTIBIOTICS
51. OTIC ANTI-INFECTIVES & ANESTHETICS
52. PROGESTATIONAL AGENTS
53. SEDATIVE HYPNOTICS
54. SMOKING CESSATION
55. STEROIDS, TOPICAL (4)
56. STIMULANTS AND RELATED AGENTS

Next Meeting

Carly Whitehouse will send available dates to P&T Committee members via email and determine which date can be best accommodated. Many members of the committee commented that keeping the meeting on Thursday nights would be most convenient.

The meeting was adjourned at 7:54 pm.